Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN45IC)

• Drug Name: AFM13 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Phase 2	[1]
Mycosis fungoides	2B01	Phase 2	[2]
Peripheral T-cell lymphoma	2A90.C	Phase 2	[2]
Lymphoma	2A80-2A86	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID: DMN45IC

Molecule-Related Drug Atlas

Drug(s) Targeting Immunoglobulin gamma Fc receptor IIIA (FCGR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFM24	DMFTZX0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
RG6296	DMEFUSJ	Multiple myeloma	2A83	Phase 1	[5]

Drug(s) Targeting Lymphocyte activation antigen CD30 (TNFRSF8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brentuximab vedotin	DMWLC57	Hodgkin lymphoma	2B30	Approved	[6]
Iratumumab	DMI874B	Lymphoma	2A80-2A86	Phase 2	[7]
SGN-30	DMJ9M5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
CAR-T cells targeting CD30	DML0KWM	Non-hodgkin lymphoma	2B33.5	Phase 2	[9]
CAR-T cells targeting CD30	DML0KWM	Non-hodgkin lymphoma	2B33.5	Phase 2	[10]
TT11X	DMW3M7X	Hodgkin lymphoma	2B30	Phase 2	[11]
TT20X	DMHGI09	Aggressive cancer	2A00-2F9Z	Phase 2	[11]
4SCAR19 and 4SCAR30	DMUYFS1	B-cell lymphoma	2A86	Phase 1/2	[12]
Anti-CD30 CAR T cells	DM8139V	Lymphoma	2A80-2A86	Phase 1/2	[13]
CART30	DMLE8T9	Hodgkin lymphoma	2B30	Phase 1/2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin gamma Fc receptor IIIA (FCGR3A)	TTIFOC0	FCG3A_HUMAN	Not Available	[4]
Lymphocyte activation antigen CD30 (TNFRSF8)	TT2GM5R	TNR8_HUMAN	Not Available	[4]

References

• [1] ClinicalTrials.gov (NCT02321592) GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [5] Clinical pipeline report, company report or official report of Genentech.
• [6] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [7] Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
• [8] The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
• [9] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [10] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [11] Clinical pipeline report, company report or official report of Tessa Therapeutics
• [12] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [13] ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
• [14] ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas